Alnylam Pharmaceuticals Inc (NAS:ALNY)
$ 165.72 8.3 (5.27%) Market Cap: 20.96 Bil Enterprise Value: 19.89 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 67/100

Alnylam Pharmaceuticals Inc at Leerink Partners Global Healthcare Conference Transcript

Feb 27, 2019 / 03:30PM GMT
Release Date Price: $85 (+4.04%)
Mani Foroohar
SVB Leerink LLC, Research Division - MD of Genetic Medicines & Senior Research Analyst

Good morning, everyone, grab your seats. Mani Foroohar, Managing Director here at SVB Leerink covering joint medicine. And I'm very happy to introduce Barry Greene from Alnylam Pharmaceuticals to give us a quick overview and have a little chat. Barry, you want to start us off?

Barry E. Greene
Alnylam Pharmaceuticals, Inc. - President

Yes. Mani, thanks for having us, and we'd like to thank the organizers of Leerink for having us here today. It's always a pleasure to give an update on the tremendous progress that we're making in translating RNAi into a whole new class of drugs.

And let me provide a quick kind of 3-, 4-minute overview, and then we can get into the questions.

So as you all know, Alnylam was founded about 16 years ago to develop RNA interference to an entirely new class of drugs. And last year, as you're well aware, we launched our first commercial drug, ONPATTRO. We'll talk more about that. The launch is going extremely

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot